Recent advances in epidemiologic, diagnostic, pathologic, and management aspects of atypical parkinsonian disorders are reviewed and placed in perspective. The implications of considering progressive supranuclear palsy and corticobasal degeneration as tauopathies, and multiple system atrophy and dementia with Lewy bodies as alpha-synucleopathies are discussed.